isoxazoles has been researched along with ursodeoxycholic acid in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Binz, J; Dennis, S; Desai, B; Goodwin, B; Jones, SA; Kliewer, SA; Liu, Y; Luo, G; MacKenzie, KI; Mansfield, TA; Numerick, MJ | 1 |
| Alawad, AS; Levy, C | 1 |
| Cai, X; Chen, ZL; Jin, F; Li, G; Li, HR; Luo, L; Ma, Q; Wang, Y; Xue, J; Yang, F; Zhao, L; Zhou, X | 1 |
| Kowdley, KV; Shah, RA | 1 |
| Bertolini, A; Bloks, VW; Chen, S; de Wit, S; Havinga, R; Jašprová, J; Jonker, JW; Mennillo, E; Rettenmeier, E; Schreuder, AB; Struik, D; Tukey, RH; Valášková, P; van der Schoor, LWE; Verkade, HJ; Vítek, L; Weber, AA | 1 |
2 review(s) available for isoxazoles and ursodeoxycholic acid
| Article | Year |
|---|---|
FXR Agonists: From Bench to Bedside, a Guide for Clinicians.
Topics: Animals; Azepines; Chenodeoxycholic Acid; Cholagogues and Choleretics; Cholestasis; Drug Evaluation, Preclinical; Gastrointestinal Agents; Hepatitis, Autoimmune; Humans; Hypertension, Portal; Indoles; Isoxazoles; Liver Cirrhosis, Alcoholic; Liver Cirrhosis, Biliary; Liver Diseases; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear; Ursodeoxycholic Acid | 2016 |
Current and potential treatments for primary biliary cholangitis.
Topics: Benzothiazoles; Bezafibrate; Bile Acids and Salts; Budesonide; Case-Control Studies; Chenodeoxycholic Acid; Cholagogues and Choleretics; Clinical Trials as Topic; Cyclosporine; Disease Progression; Glucocorticoids; Homeostasis; Humans; Immunologic Factors; Immunosuppressive Agents; Isoxazoles; Liver Cirrhosis, Biliary; Liver Transplantation; Peroxisome Proliferator-Activated Receptors; Receptors, Cytoplasmic and Nuclear; Rituximab; Treatment Outcome; United States; United States Food and Drug Administration; Ursodeoxycholic Acid | 2020 |
3 other study(ies) available for isoxazoles and ursodeoxycholic acid
| Article | Year |
|---|---|
Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Transporters; Carrier Proteins; Cholestasis; Cytoprotection; DNA-Binding Proteins; Isocyanates; Isoxazoles; Male; Membrane Transport Proteins; Naphthalenes; Organic Anion Transporters, Sodium-Dependent; Organic Anion Transporters, Sodium-Independent; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Steroid 12-alpha-Hydroxylase; Symporters; Taurine; Transcription Factors; Ursodeoxycholic Acid | 2003 |
Effects of corilagin on alleviating cholestasis via farnesoid X receptor-associated pathways in vitro and in vivo.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Cell Survival; Cells, Cultured; Cholestasis; Cholesterol 7-alpha-Hydroxylase; Cytochrome P450 Family 7; Dexamethasone; Down-Regulation; Glucosides; Glucuronosyltransferase; Humans; Hydrolyzable Tannins; Isoxazoles; Liver; Male; Organic Anion Transporters, Sodium-Dependent; Pregnenediones; Primary Cell Culture; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Rats; Receptors, Cytoplasmic and Nuclear; RNA, Small Interfering; Steroid Hydroxylases; Sulfotransferases; Symporters; Up-Regulation; Ursodeoxycholic Acid | 2018 |
Potential of therapeutic bile acids in the treatment of neonatal Hyperbilirubinemia.
Topics: Animals; Bile Acids and Salts; Bilirubin; Chenodeoxycholic Acid; Hyperbilirubinemia, Neonatal; Ileum; Isoxazoles; Liver; Mice; Rats, Gunn; Receptors, Cytoplasmic and Nuclear; Treatment Outcome; Ursodeoxycholic Acid | 2021 |